A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Stage IIIb or IV Non-Small-Cell Lung Cancer

Trial Profile

A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Stage IIIb or IV Non-Small-Cell Lung Cancer

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Ganetespib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms GALAXY-1
  • Sponsors Synta Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Aug 2015 According to a Synta Pharmaceuticals media release, data from this study were published in the first issue of the journal Annals of Oncology.
    • 08 May 2014 Status changed from active, no longer recruiting to completed as reported by a Synta Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top